Press Releases

  • Dec. 16, 2019 Bioasis Announces Bridge Financing

     THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of… Read more »

  • Dec. 5, 2019 Bioasis Announces Annual General Meeting Results

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »

  • Dec. 4, 2019 Bioasis Appoints Consultant Chief Medical Officer and Nominates Medical Oncology Advisory Board

    Dr. John DeGroot, Dr. Hope Rugo and Dr. Javier Cortés Join Medical Oncology Advisory Board GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in… Read more »

  • Nov. 27, 2019 Bioasis to Host Annual General Meeting Webcast on December 5, 2019

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »

  • Nov. 25, 2019 Bioasis Announces Director Resignation

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and… Read more »

  • Nov. 14, 2019 Bioasis Announces Issuance of Japanese Patent Relating to xB3™ Platform Technology for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today… Read more »

  • Nov. 8, 2019 Bioasis Completes Financing Transactions

    THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery… Read more »

  • Oct. 28, 2019 Bioasis Announces Bridge Financing

    THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery… Read more »

  • Oct. 25, 2019 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced it has filed its unaudited financial… Read more »

  • Sep. 23, 2019 Bioasis Announces Proposed Private Placement

    THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the… Read more »